Targeting for drug delivery and imaging: An overview of the state of the art in cancer;Vectorisation à visée thérapeutique ou diagnostique: Une synthèse de l'état de l'art dans le domaine du cancer

Bulletin du Cancer

Volumn 98, Issue 11, 2011, Pages 1363-1371

  Dubernet, Catherine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cancer; Diagnostics; Nanotechnology; Stealth; Targeting

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE VECTOR; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASM; REVIEW;

EID: 82455181871     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1468     Document Type: Review

References (43)

1. Vauthier C, Couvreur P. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23 : 1417-50. (Pubitemid 43993807)
2. Morrow KJ, Bawa R, Wei C. Recent advance in basics and clinical nanomedicine. Med Clin N Am 2007; 91 : 805-43. (Pubitemid 47364736)
3. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59 : 491-504. (Pubitemid 47259227)
4. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26 : 1025-58.
5. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnol 2007; 2 : 751-60. (Pubitemid 350223348)
6. Manchester M, Singh P. Virus-based nanoparticles: platform technologies for diagnostic imaging. Adv Drug Deliv Rev 2006; 58 : 1505-22. (Pubitemid 44829893)
7. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicine: from toxicology to pharmacology. Adv Drug Deliv Rev 2006; 58 : 1460-70. (Pubitemid 44822607)
8. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater 2011; in press doi:10.1002/adma.201102313.
9. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after iv administration in reticulosarcoma M5076 metastasis bearing mice. Cancer Chemother Pharmacol 1990; 26 : 122-6. (Pubitemid 20153803)
10. Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Rel 2000; 68 : 283-9. (Pubitemid 30488905)
11. Barraud L, Merle P, Soma E, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42 : 736-43.
12. Colin de Verdière A, Dubernet C, Némati F, et al. Reversion of the multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 1997; 76 : 198-205.
13. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54 : 631-51. (Pubitemid 35247520)
14. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011; 14 : 150-3.
15. Bildstein L, Dubernet C, Marsaud V, et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J Control Rel 2010; 147 : 163-70.
16. Couvreur P, Reddy H, Mangenot S, et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 2008; 4 : 247-53. (Pubitemid 351271158)
17. Couvreur P, Stella B, Reddy LH, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Letters 2006; 6 : 2544-8. (Pubitemid 46076946)
18. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58 : 1471-504. (Pubitemid 44820503)
19. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63 : 136-51.
20. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58 : 1532-55. (Pubitemid 44822608)
21. Torchilin VT. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9 : E128-47.
22. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv Drug Deliv Rev 2011; 63 : 170-83.
23. Van Vlerken LE, Vyas TK, Amiji MM. Polyethylene glycol modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007; 24 : 1405-14. (Pubitemid 46988224)
24. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10 : 3708-16.
25. Liu Y, Zhang B, Yan B. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel. Int J Mol Sci 2011; 12 : 4395-413.
26. Ferrari M. Cancer nanotechnologies: opportunities and challenges. Nat Rev Cancer 2005; 5 : 161-71.
27. Koo YL, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006; 58 : 1556-77. (Pubitemid 44820505)
28. Brigger I, Morizet J, Aubert G, et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 2002; 303 : 928-36. (Pubitemid 35424373)
29. Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010; 7 : 3.
30. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007; 120 : 2527-37. (Pubitemid 46651272)
31. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 2011; 63 : 161-9.
32. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor targeted liposomes: doxorubicin loaded long circulating liposomes modified with anticancer antibody. J Control Release 2004; 100 : 135-44.
33. Vauthier C, Tsapis N, Couvreur P. Nanoparticles: heating tumors to death? Nanomedicine 2011; 6 : 99-109.
34. Hillaireau H, Couvreur P. Nanocarrier's entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009; 66 : 2873-96.
35. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting?. Eur J Pharm Biopharm 2008; 68 : 112-28. (Pubitemid 350181412)
36. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nanodevice (MEND) for gene delivery to tumors based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011; 63 : 152-60.
37. Kelkar S, Reineke TM. Theranostics: combining imaging and therapy. Bioconjugate Chem 2011; in press doi:10.1021/bc200151q.
38. Matsumura Y. Preclinical and clinical studies of NK012, an SN- 38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2011; 63 : 184-93.
39. Melancon MP, Zhou M, Li C. Cancer theranostics with near infrared light-activable multimodal nanoparticles. Acc Chem Res 2011; doi:10.1021/ar200022e.
40. Douziech-Eyrolles L, Marchais H, Herve K, et al. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine 2007; 2 : 541-50.
41. Sonvico F, Dubernet C, Colombo P, Couvreur P. Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des 2005; 11 : 2095-105.
42. Llevot A, Astruc D, Application of vectorized gold nanoparticles to the diagnostic and therapy of cancer. Chem Soc Rev 2011; in press doi:10.1039/c1cs15080d.
43. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58 : 1456-9. (Pubitemid 44820502)